The stock of Rockwell Medical Inc (NASDAQ:RMTI) hit a new 52-week low and has $3.68 target or 11.00% below today’s $4.14 share price. The 8 months bearish chart indicates high risk for the $213.20M company. The 1-year low was reported on Nov, 8 by Barchart.com. If the $3.68 price target is reached, the company will be worth $23.45M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 1.31M shares traded hands or 349.48% up from the average. Rockwell Medical Inc (NASDAQ:RMTI) has declined 19.35% since April 5, 2016 and is downtrending. It has underperformed by 21.30% the S&P500.
Analysts await Rockwell Medical Inc (NASDAQ:RMTI) to report earnings on November, 14. They expect $-0.10 earnings per share, down 100.00% or $0.05 from last year’s $-0.05 per share. After $-0.11 actual earnings per share reported by Rockwell Medical Inc for the previous quarter, Wall Street now forecasts -9.09% EPS growth.
According to Zacks Investment Research, “Rockwell Medical Technologies, Inc. manufactures hemodialysis concentrates and dialysis kits, and sells, distributes and delivers such concentrates and dialysis kits, as well as other ancillary hemodialysis products, to hemodialysis providers in the United States. Hemodialysis is a process which is able to duplicate kidney function in patients whose kidneys have failed to function properly.”
Insitutional Activity: The institutional sentiment decreased to 0.9 in 2016 Q2. Its down 0.26, from 1.16 in 2016Q1. The ratio dived, as 11 funds sold all Rockwell Medical Inc shares owned while 28 reduced positions. 9 funds bought stakes while 26 increased positions. They now own 10.76 million shares or 10.05% less from 11.96 million shares in 2016Q1.
Pnc Group Incorporated Incorporated accumulated 0% or 285 shares. Metropolitan Life Ny accumulated 43,247 shares or 0% of the stock. State Board Of Administration Of Florida Retirement Systems reported 26,889 shares or 0% of all its holdings. Paloma Prns Communications has 0% invested in the company for 16,496 shares. Schwab Charles Management owns 78,700 shares or 0% of their US portfolio. New York State Common Retirement Fund holds 0% of its portfolio in Rockwell Medical Inc (NASDAQ:RMTI) for 40,600 shares. Oakworth Capital has 2,500 shares for 0.01% of their US portfolio. Ladenburg Thalmann Financial Services, a Florida-based fund reported 27,490 shares. Balasa Dinverno And Foltz Lc has 35,800 shares for 0.05% of their US portfolio. Interocean Cap Ltd Limited Liability Company holds 0.04% or 19,165 shares in its portfolio. The New York-based Intll Gru Inc has invested 0% in Rockwell Medical Inc (NASDAQ:RMTI). Credit Suisse Ag reported 53,925 shares or 0% of all its holdings. Benchmark has 0.17% invested in the company for 28,000 shares. Natixis, a France-based fund reported 30,000 shares. Reilly Limited holds 200 shares or 0% of its portfolio.
Insider Transactions: Since August 12, 2016, the stock had 0 insider purchases, and 4 insider sales for $105,555 net activity. The insider HOLT KENNETH L sold $8,288.
More notable recent Rockwell Medical Inc (NASDAQ:RMTI) news were published by: Fool.com which released: “3 Ways Rockwell Medical Inc. Could Turn Things Around” on October 07, 2016, also Fool.com with their article: “3 Predictions for Rockwell Medical Inc. in 2016” published on December 10, 2015, Fool.com published: “Will Rockwell Medical Inc. Sink or Swim?” on April 06, 2016. More interesting news about Rockwell Medical Inc (NASDAQ:RMTI) were released by: Fool.com and their article: “Why Rockwell Medical, Inc. Shares Are Crashing Today” published on March 01, 2016 as well as Fool.com‘s news article titled: “Rockwell Medical Stock Upgraded: What You Need to Know” with publication date: August 19, 2016.
RMTI Company Profile
Rockwell Medical, Inc. (Rockwell), incorporated on October 25, 1996, is a biopharmaceutical firm targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with services and products for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Firm operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company’s lead branded drug, Triferic is indicated for iron maintenance.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.